Managing Covid-19 in patients with heart failure: current status and future prospects.
Expert Rev Cardiovasc Ther
; 20(10): 807-828, 2022 Oct.
Article
in English
| MEDLINE | ID: covidwho-2051004
ABSTRACT
INTRODUCTION:
COVID-19 may contribute to decompensation of previously stable chronic HF or cause a de-novo heart failure, which may come from the hyperinflammatory response and subsequent increase in metabolic demand. AREAS COVERED Two independent investigators searched MEDLINE (via PubMed), Europe PMC, and ScienceDirect databases with the following search terms COVID-19, heart failure, COVID-19 drugs, heart failure drugs, and device therapy. All of the included full-text articles were rigorously evaluated by both authors in case there was disagreement about whether research should be included or not. In total, 157 studies were included and underwent extensive reading by the authors. EXPERT OPINION The World Health Organization (WHO) and the National Institute of Health (NIH) have published COVID-19 drug recommendations, although recommendations for HF-specific drug choices in COVID-19 are still lacking. We hope that this review can answer the void of comprehensive research data regarding the management options of HF in the COVID-19 condition so that clinicians can at least choose a more beneficial therapy or avoid combination therapies that have a high burden of side effects on HF; thus, morbidity and mortality in COVID-19 patients with HF may be reduced.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Heart Failure
Type of study:
Experimental Studies
/
Reviews
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Expert Rev Cardiovasc Ther
Journal subject:
Vascular Diseases
/
Cardiology
/
Therapeutics
Year:
2022
Document Type:
Article
Affiliation country:
14779072.2022.2132230
Similar
MEDLINE
...
LILACS
LIS